Dr
Actinium Pharmaceuticals
Author in the following contributions
- Highly Effective Treatment of CD38 Positive Experimental Lymphoma with 225Actinium-Daratumumab.
- Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225
- Impact of Target Cell Number on Target cell and Tissue Dose for Antibody-Mediated delivery of Alpha-Emitters
- Radiolabeling of DOTA-conjugated Lintuzumab with 225Ac: Comparison of Th-229-produced and High-Energy Proton Accelerator-produced 225Ac